Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Eli Lilly and Co (NYSE:LLY)

84.18
Delayed Data
As of Mar 24
 -0.24 / -0.28%
Today’s Change
64.18
Today|||52-Week Range
86.14
+14.45%
Year-to-Date
Eli Lilly to Invest $850M in U.S. Capital Projects This Year
Mar 24 / TheStreet.com - Paid Partner Content
European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details
Mar 20 / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
Mar 24 / Zacks.com - Paid Partner Content
European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
Mar 20 / TheStreet.com - Paid Partner Content
AstraZeneca Stock Rising in '17: What's Working in its Favor?
Mar 23 / Zacks.com - Paid Partner Content
What are Sanofi's (SNY) Strengths and Challenges in 2017?
Mar 17 / Zacks.com - Paid Partner Content
Merck Closes Acquisition of Controlling Stake in Vallee S.A
Mar 23 / Zacks.com - Paid Partner Content
Here's Why Aratana Therapeutics Inc. Is Getting Clobbered
Mar 14 / MotleyFool.com - Paid Partner Content
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
Mar 22 / Zacks.com - Paid Partner Content
Better Buy: Eli Lilly and Company vs. Pfizer
Mar 13 / MotleyFool.com - Paid Partner Content
Harbour Capital Advisors, LLC Buys Amazon. ...
Mar 21 / GuruFocus News - Paid Partner Content
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays
Mar 13 / Zacks.com - Paid Partner Content
Lilly's Breast Cancer Combo Drug Phase III Results Positive
Mar 21 / Zacks.com - Paid Partner Content
Graduates reveal the strengths and weaknesses of online MBAs
Mar 05 / FT.com - Paid Partner Content
Novartis (NVS) Announces Positive Data on Heart Failure Drug
Mar 20 / Zacks.com - Paid Partner Content